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Introduction
Decision making in the context of the 10-minute
consultation can be challenging, and the advent of
personalisedmedicinemightmake the task evenmore
complex. The concept of personalised medicine had
been borne out of a combination of: improvements
in our knowledge about the human genome; under-
standing of biomarkers and other developments in
basic science; and advances in computational power.1
Personalised medicine is generally described as the
dividing of patients into groups on the basis of their
biological or genomic make-up; and personalising
management regimes for these groups. However, as
clinicians we sit with individual patients and need to
develop individual strategies for every patient, and
have some insight into whether they are getting better
or getting worse with often very few biochemical
measures at our disposal; and, although our com-
puterised medical record systems may hold a decade
ABSTRACT
Background Personalised medicine involves cus-
tomising management to meet patients’ needs. In
chronic kidney disease (CKD) at the population
level there is steady decline in renal function with
increasing age; and progressive CKDhas been deﬁned
as marked variation from this rate of decline.
Objective To create visualisations of individual
patient’s renal function anddisplay smoothed trend
lines and conﬁdence intervals for their renal func-
tion and other important co-variants.
Method Applying advanced pattern recognition
techniques developed in biometrics to routinely
collected primary care data collected as part of the
Quality Improvement in Chronic Kidney Disease
(QICKD) trial. We plotted trend lines, using re-
gression, and conﬁdence intervals for individual
patients.Wealso createdavisualisationwhichallowed
renal function to be compared with six other co-
variants: glycated haemoglobin (HbA1c), body mass
index (BMI), BP, and therapy. The outputs were
reviewed by an expert panel.
Results We successfully extracted and displayed
data. We demonstrated that estimated glomerular
ﬁltration (eGFR) is a noisy variable, and showed
that a large number of people would exceed the
‘progressive CKD’ criteria. We created a data dis-
play that could be readily automated. This display
was well received by our expert panel but requires
extensive development before testing in a clinical
setting.
Conclusions It is feasible to utilise data visualisa-
tion methods developed in biometrics to look at
CKD data. The criteria for deﬁning ‘progressive
CKD’ need revisiting, as many patients exceed them.
Further development work and testing is needed
to explore whether this type of data modelling and
visualisation might improve patient care.
Keywords: automatic data processing, chronic dis-
ease, diabetes mellitus, longitudinal studies, person-
alised medicine, renal insuﬃciency
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or more of readily available data;2,3 though it is not
necessarily easy to interpret. Visualising longitudinal
patient data may help their clinician observe the
interplay between markers of disease and therapy on
an individual patient basis. Longitudinal data held in
electronic patient records may provide insight into
whether people are responsive or not to therapy.
Chronic kidney disease (CKD) is an important
condition which aﬀects between 5% and 10% of the
population;4 and interventions which can aﬀect out-
come, particularly strict control of systolic BP,5 can be
implemented in primary care. It is important because
it is associated with an increased risk of major cardio-
vascular events and death; broadly similar to the excess
mortality and morbidity associated with diabetes.6
There is clear guidance how to manage CKD in the
adult population,7,8 however, GPs ﬁnd the guidance
challenging to implement,9 and lack conﬁdence in
managingCKDcomparedwith other comorbidities.10
Diﬃculties include that renal function, primarily meas-
ured using estimated glomerular ﬁltration rate (eGFR),
ﬂuctuates markedly; this because it is derived from
serum creatinine, primarily a product of muscle break-
down and protein containing food. The national
guidance for management of CKD in adults suggests
that a decline in eGFR of >5 ml/min in one year or a
decline of >10ml/min in ﬁve years should be regarded
as rapid decline and referred for specialist care. Data
from the Quality Improvement in Chronic Kidney
Disease (QICKD) trial11 suggests that the decline seen
year on year in the population in eGFR is between 0.4
and 0.7 ml/min per year. Figure 1 shows the decline in
eGFR during adult life and superimposed are the rates
of decline where referral is recommended.
However, looking at the population as awhole there
is considerable ﬂuctuation in creatinine, with much
of this ﬂuctuation exceeding the decline in eGFR of
>5 ml/min in one year or >10 ml/min in ﬁve years
recommended as thresholds for referral.12 For example,
in theQICKD trial we found that 31% (16 587/53 322)
people with two eGFR readingsmore than a year apart
had their creatinine ﬂuctuate by over 5 ml/min in one
year (Figure 2); clearly it would not have been feasible
to refer them all.
Figure 1 The rateof decline in eGFRwith increasing age formales, females and thepopulation; superimposed
are triangles to represent accelerated decline where referral is recommended. From QICKD study baseline
data (n= 50331, people with CKD)
Figure 2 Fluctuation between minimum and maximum eGFR over one and ﬁve years; the vertical bold lines
indicate a decline of over 5 and 10 ml/min in eGFR, which should be referred to specialist care
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Unfortunately combining our knowledge about the
population trend and how eGFR ﬂuctuates in the
population does not help greatly with the manage-
ment of individual patients. In the clinical scenario the
responsible clinician has to decide whether the change
in eGFR is part of normal ﬂuctuation or not for the
individual patient in front of them.We carried out this
pilot study to showwhether we could use visualisation
techniques to display trends in renal function in
individual patients; and indicate whether a new value
is part of normal ﬂuctuation or an abnormal ﬁnding.
Method
The aim of the pilot is to demonstratemethods of data
visualisation to display; (1) ﬂuctuation among indi-
vidual patients within a population with apparently
smooth change; and (2) create pilot outputs from
routine data that can be used to help manage individ-
ual patients; usingmethodswhich can be readilymade
machine processable. Longitudinal displays of routine
data have been proposed as a method that might help
to improve care.13 We worked with a small panel of
clinical experts in CKD, nephrologists, researchers and
general practitioners, to understand how improved
display of data might improve clinical management.
The expert panel conﬁrmed the need for a data-
presentation methodology that is personalised and
patient-centred. We have set out in the introduction
how current methodologies, based on analysis at the
population level, are not adequate because the trend in
each patient is aggregated; the methodological chal-
lenge is to produce an improved version.
We transferred techniques developed from bio-
metrics to medical science because both domains share
the following similarities: they deal with signals gen-
erated from biology processes; both types of data can
be 1D, 2D, 3D or 3D+time; both type of data are
longitudinal in nature, often extending over many
years; the types of data samples are collected in open
environments, or in-vivo, that is, the experimenter has
minimal control over the experimental setting. The
last characteristic makes the data modelling problem
extremely challenging.
The biometric methods applied to the data model-
ling problem in CKD are as follows:
. estimate the biometric performance over time – in
the case of CKD we applied this approach to eGFR
as the key measure of renal function14
. the model parameters: primarily how eGFR ﬂuctu-
ates with age, is calibrated using a regression model
that hypothesises what is acceptable change over
time15
. the method produces an output at the individual
patient level which might ultimately be capable of
supporting improved medical decision making16
. the method that handles missing values in data
modelling17
. a method that models a hypothesis (person identity)
taking contextual covariates into account.18
The assumption in the method is that that the bio-
medical signal is generated by a steady process that is
corrupted by daily biologically induced ﬂuctuation
and other activities unaccounted for (collectively con-
sidered as ‘noise’). Creatinine production is known to
be generated bymuscle breakdown and its serum level
is related tomusclemass; the steady process. Generally
as renal function declines blood levels of creatinine
rise; again a steady process of creatinine rising and
eGFR falling with increasing age (Figure 1). However,
there are a number of factors which can cause
creatinine to change; and create ‘noise’, or ﬂuctuation.
Eating protein based meals and increased cell break-
down (due to illness or treatments for cancer) can
increase serum creatinine (SCr); and eating little and
reducingmusclemass (e.g. an amputation) can reduce
it. eGFR is related to the inverse of SCr, so as SCr rises
with deteriorating renal function so eGFR falls.
The data for the QICKD trial are held on a secure
MySQL19 database. Customised data extraction queries
were developed to provide test variables for this exer-
cise. These queries mimic those that might be used to
extract data from live clinical systems rather than from
a research database.
We ﬁtted a regression line to the eGFR values
available on a per patient basis, and for the entire popu-
lation. This regression line has the eﬀect of smoothing
the ‘noise’ or ﬂuctuation in eGFR. The regression line
also enables 95% conﬁdence intervals to be plotted,
giving some indication for that individual patient
whether their ﬂuctuation is within an acceptable limit
based on previous change or potentially greater. We
plotted ﬁtted regression curves, superimposed with
the original data, for a random selection of 20 patients
with over 15 years’ data.
We then developed a data display data for an indi-
vidual patient with CKD, and diabetes. We displayed:
. eGFR as a measure of renal function
. glycated haemoglobin (HbA1c) – a measure of the
quality of diabetes control (using International
Federation of Clinical Chemists (IFCC) units – the
nearer to 55 mmol/mol the better the control)
. body mass index (BMI) – a measure of obesity
(weight in kg/height in metres squared) BMI over
30 kg/m2 deﬁnes obesity
. blood pressure (BP) – measures as systolic and
diastolic (a BP of under 130/80 is recommended)
. prescribed Metformin – this is a ﬁrst line anti-
diabetic drug – which is useful because it helps
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reduce appetite but has been associated with im-
paired renal function 20
. prescribed other oral anti-diabetic drugs (OAD) –
these drugs are eﬀective in controlling diabetes, but
by lowering blood glucose and increasing appetite
and result in weight gain
. we also plotted the consumption of aspirin, as an
example of a cardiovascular medication.
We plotted a regression line and 95% conﬁdence
intervals for the variation in eGFR, HbA1c and BMI.
We initially attempted this with BP but it involved the
display of too many lines. We plotted drug consump-
tion on consumption of tablets or item per 28 days.
We weighted up the pros and cons of using a medi-
cines possession ratio, as we have previously used for
osteoporosis medication;21 however, as we may not
always know the intended dose of medication we
considered that the number of tablets or items per
28 days would be of most value.
Ethical considerations
The QICKD Trial is ethically approved and this
study’s details are recorded at the International Stan-
dard Randomised Controlled Trial Number Register
(ISRCTN56023731).22
Results
Wedisplay howbeneath the smooth and linear decline
in eGFR (Figure 1) there is considerable noise/ﬂuctu-
ation among individuals. The ﬁtted regression curves
which are superimposed with the original data for 20
patients are shown in Figure 3. For example: on the
extreme right of the ﬁgure is a person for whom we
have data from their late 80s through to nearly 100
years of age. During this period the patient’s ‘smoothed’
eGFR rises from 42 ml/min to 56 ml/min. However,
their ﬂuctuating eGFR changes from 48ml/min down
to its lowest level 39 ml/min eventually ﬁnishing at
58 ml/min. For this individual, although their trend
overall was one of improvement, theymight have been
referred on the basis of their rapidly declining eGFR.
We presented these ﬁgures to a panel of CKD experts;
they thought this approach oﬀered more than just
comparing individuals with the population trend
(Figure 1). They felt that the smoothed data made it
much easier to observe trends in patients and reported
that data presented in this way had the potential to
enable an estimate to be made of the annual rate of
change of eGFR in an individual. They speculated that
if that could be based on their smoothed regression
line, and whether this more accurately represented their
underlying change in renal function. They felt that
individual case examination ‘must’ be superior to the
current approach which is to compare an individual’s
change with arbitrarily set limits which deﬁne an accel-
Figure 3 Fluctuation in individual’s eGFR. This ﬁgure shows raw values (bold ﬂuctuating line) then a
regression line (the ﬁtted curve) for each individual, we also display as dotted lines 95% conﬁdence intervals
for the regression line. All the patients have at least 10 years data.
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erated decline (i.e. >5 ml/min on one year, >10 ml/
min in 5 years).
We developed a viewer for individual patient data.
This data visualisation displays anonymised, real
patient data for one patient drawn from the QICKD
trial. This is shown as an exemplar of how machine
processable data might be displayed (Figure 4). For
this single patient we display data from between the
ages of 63 and 81 years. There is only four years’ eGFR
data, but this shows an initial decline then a levelling
oﬀ in that decline. Glycated haemoglobin (HbA1c)
has risen steadily between age 70 and 78 years, but has
plateaued and moved back towards target values over
the last 3–4 years. The improvement inHbA1c appears
to be mirrored by a change in BMI, a fall in BMI
appears to be associated with a fall in HbA1c. Systolic
BP generally appears to have been higher in the last
decade. The step up in BP is associated with the time
when metformin was ﬁrst prescribed, which in turn
may have been associated with a diagnosis of diabetes.
One short period on anOADwas associated with a fall
in HbA1c, however, the association between falling
HbA1c and BMI appears stronger.
Initial opinion from our panel was generally posi-
tive. They felt this type of computer generated display
might signiﬁcantly improve care in complex cases.
They thought that the change in BMI and HbA1c may
have been hard to discern in usual care records, some
of which allow listing or graphing of variables but not
as many variables, nor as succinctly. No existing
providers they were aware of provide regression lines
to illustrate the trend, or conﬁdence intervals to give
some idea if a value is an outlier. However, they also
thought that considerable testing was needed of the
combinations of variables needed for eﬀective man-
agement. For example, should proteinuria measures
always be displayed with eGFR; haemoglobin with
aspirin, other anticoagulants, and non-steroidal anti-
inﬂammatory drugs; the need to display blood pressure
medications, maybe angiotensin modulating drugs
separately; and others.
Discussion
Principal ﬁndings
We have successfully demonstrated that routine data
in UK practice had signiﬁcant amounts of longitudi-
nal data. We have also shown that smooth trends
in eGFR at the population level are not matched by
changes at the individual patient level. Additionally,
many patients have changes in eGFR which exceed
the national guidance deﬁnition of ‘rapidly declining’
eGFR. Finally, we have created a computer generated
visual display of a range of variables and ﬁtted curves
(Figure 4); which was well received by a small panel.
Figure 4 Pilot visualisationof health data for a personwith diabetes and chronic kidney disease: charts to help
practice personalised medicine. The chart shows the patient’s age, any data for eGFR, HbA1c, BMI, BP,
metformin, OADs, or aspirin
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Implications of the ﬁndings
Longitudinal data is uniquely and readily available in
primary care and other computer systems and can be
harnessed to improve individual patient care. eGFR is
a ‘noisy’ variable with a great deal of ﬂuctuation. So
many people appear to exceed the deﬁnition of ‘rap-
idly declining’ eGFR thatwe think this requires review.
This early pilot suggests that if they can be shown to be
valid, that trend lines and conﬁdence intervals of the
sort we have displayed may be of great value to clin-
icians in managing individual patients.
Comparison with the literature
We have already reported issues with creatinine ﬂuc-
tuation at the population level and these individual
patient trends are compatible with this. Much of the
important literature about the rationale for visualisa-
tion has been reviewed by Samal et al and this work is
entirely compatible with their position paper. Person-
alised medicine is likely to be here to stay and this
initiative may provide pointers towards how we can
observe key data. Similar approaches have been pro-
posed in cancer management.23 In developing this
intervention further we will need to follow advice and
best practice on how to develop a new complex
intervention.24
There are some similarities in this approach and
those adopted in statistical process control (SPC)25,26
though statistical process control proposes methods
for observing data and does not encompass the poten-
tially automated methods of data extraction which
form part of this method.
Limitations of the method
There are many limitations to this pilot. We don’t
know if our assumptions about the underlying trends
are correct, or whether our conﬁdence intervals are
valid. We have not optimised the list of variables we
display. These data have been extracted from a re-
search database which is completely under our control
rather than involving live data extraction from a
computerised medical record system. Most import-
antly no studies have yet been carried out, either
simulated or in clinical practice, suggesting that this
approach improves patient care.
Call for further research
It should be possible to develop modelling software
capable of analysing and modelling NHS-extracted
data with time-varying covariates and factors, as well
as other contextual factors including economic depri-
vation and lifestyle. The software can be used by
researchers inmedical informatics, biomedical science
and primary care doctors, giving an overview of the
known history of a patient. This represents a major
change considering that a typical piece of software in
primary care practices provides only snapshot views of
a patient divided into diﬀerent tabs of measurements
and prescriptions, thus failing to give an overall
longitudinal picture of the patient’s history compared
with those generated here (Figure 4).
Such tools might be used to distinguish patients
with CKD who are more likely to progress to compli-
cations and more serious illness from those who are
less likely. There may also be potential to quantify the
impact of known and new associations with pro-
gression.
Conclusions
This study is a small ﬁrst step towards the generation
of visualisation and modelling tools that can model
longitudinal data on a personal basis. There is poten-
tial for this to be used to oﬀer more personalised care.
However, there are many stages needed ﬁrst, to develop
and test a complex intervention. eGFR is a noisy
variable with considerable ﬂuctuation, current deﬁ-
nitions of ‘rapid decline’ as a threshold for referral
appear incorrect. Computer generated visualisation of
longitudinal data may provide a mechanism for im-
proving care.
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